HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a $7 price target on the company's stock.
November 14, 2023 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Spero Therapeutics and maintained a $7 price target.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on Spero Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100